JanOne Inc. has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain. JanOne is developing Jan123 (a novel formulation of low dose naltrexone) to treat CRPS, an orphan disease with no current FDA-approved treatments. CRPS leaves patients in debilitating pain and suffering and, as a result, often patients resort to opioid pain medications.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.26 USD | +8.65% |
|
+18.32% | +307.21% |
07-10 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
07-10 | Sector Update: Health Care Stocks Advance in Afternoon Trading | MT |
1st Jan change | Capi. | |
---|---|---|
+307.21% | 26.38M | |
+25.83% | 47.96B | |
+0.69% | 42.45B | |
+44.13% | 41.47B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- ALTS Stock
- News ALT5 Sigma Corporation
- Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain